{"success":true,"data":{"pressRelease":{"id":"34323","rtpr_id":"nPn2RgVmla","ticker":"7666","exchange":"HKEX","all_tickers":["7666"],"title":"METiS TechBio, the World's First Publicly Listed AI-Powered Drug Delivery Company, Debuts on the Hong Kong Stock Exchange, \"The SpaceX of Pharmaceuticals\" Ushers in a New Era of Biopharmaceuticals","author":"PR Newswire","published_at":"2026-05-14T02:10:01.569Z","article_body":"METiS TechBio, the World's First Publicly Listed AI-Powered Drug Delivery Company, Debuts on the Hong Kong Stock Exchange, \"The SpaceX of Pharmaceuticals\" Ushers in a New Era of Biopharmaceuticals\n\nPR Newswire\n\nHONG KONG, May 13, 2026\n\nHONG KONG, May 13, 2026 /PRNewswire/ -- METiS TechBio (7666.HK), a tech-bio\ncompany focused on AI-powered nanodelivery innovation, today successfully\nlisted on the Hong Kong Stock Exchange (HKEX), becoming the world's first\npublicly listed AI-powered drug delivery company and the first AI-powered\nlarge-molecule biopharmaceutical company listed on the Hong Kong market. With\nthe goal of becoming the \"SpaceX of pharmaceuticals,\" METiS TechBio has,\nwithin six years of its founding, become the fastest unicorn in China's AI\npharmaceutical sector to reach the IPO milestone.\n\nMETiS TechBio's IPO was jointly sponsored by Jefferies, Deutsche Bank\nSecurities Asia and CITIC Securities (Hong Kong). A total of 201,229,000 H\nshares were offered globally, raising over HKD 2.1 billion in proceeds and\nmarking the largest healthcare IPO fundraising in Hong Kong so far in 2026.\nThe Hong Kong public offering was oversubscribed by more than 6,900 times,\nlocking up over HKD 730 billion in subscription funds, representing the\nhighest subscription amount for the Hong Kong public offering among healthcare\nIPOs in Hong Kong so far in 2026. For the international placing, the Company\nreceived orders from more than 280 institutional investors and recorded 82\ntimes oversubscription for the allocable tranche, also marking the highest\ninternational placing oversubscription multiple among healthcare IPOs in Hong\nKong so far in 2026.\n\nMETiS TechBio's Hong Kong IPO once again set a record for AI pharmaceutical\nIPOs in Hong Kong with a top-tier lineup of 18 cornerstone investors\nsubscribing for a total of USD 148 million, securing comprehensive support\nfrom \"global asset managers + specialized healthcare funds + AI technology\nfunds + state-level funds + Chinese public fund managers.\" Among them,\nBlackRock, the world's largest asset manager, led the subscription with USD 50\nmillion. Global asset management giants and ultra-long-term funds including\nUBS Asset Management Singapore, Mirae Asset of South Korea, and ORIX\nCorporation of Japan collectively made allocations. Guofengtou Innovation\nInvestment Fund, a state-level fund, made its first investment in the AI\npharmaceutical sector. Internationally renowned specialist healthcare funds,\nincluding Deerfield, RTW and Lake Bleu Capital, participated in the\ninvestment, while leading technology investment institutions, including Walden\nInternational, Hillhouse Capital and IDG Capital, also expanded their presence\ninto the sector. Top Chinese public fund managers including GF Fund, ICBC UBS\nAsset Management, China Asset Management, and Fullgoal Fund also made a rare\njoint appearance as subscribers with lock-up commitments. This fully\ndemonstrates that AI nanodelivery technology has risen to the level of a\nnational strategic priority and key area of support, and has become a critical\ntechnology driving future growth and breakthroughs in global\nbiopharmaceuticals.\n\n(https://mma.prnewswire.com/media/2979048/image1.html)\n\nDr. Chris Lai, Co-Founder, Chairman and Chief Executive Officer of METiS\nTechBio, stated:\n\n\"The future of biomedicine will no longer be simply about 'taking medicine\nwhen one falls ill.' METiS TechBio's ambition is to harness AI to build\nnano-rockets that can navigate with precision through the inner space of the\nhuman body's 30 trillion cells, write the code of nucleic acids and proteins\ninto cells, and reprogram diseased and aging cells into healthy cells. This\nwas our founding aspiration, and it is the mission to which we will dedicate\nour lives. The IPO marks a new starting point for us to accelerate forward,\nand we will strive to live up to the support and trust we have received from\nall sectors.\"\n\n(https://mma.prnewswire.com/media/2979049/image2.html)\n\n \n\n * Proprietary World-First AI Nanodelivery Platform, Creating the First-Ever\nData, Algorithms, and Models for AI for Nano\nMETiS TechBio's core competitiveness stems from NanoForge, its proprietary\nworld-first AI nanodelivery platform. The Company has built the world's\nlargest ionizable lipid library at the scale of tens of millions,\nindependently developed the world's only algorithm for de novo lipid\ngeneration and lipid language model, established the world's first end-to-end\nlipid and lipid nanoparticle (LNP) screening platform, and created the world's\nfirst AI-powered multiscale simulation platform for small-molecule formulation\ndevelopment.\n\nNanoForge encompasses AI foundation models, METiS AI agents, quantum chemistry\nand molecular dynamics simulations, and an AI-driven high-throughput screening\nplatform, serving as the foundation of the Company's proprietary AI-driven\nnanotechnology innovation system. Building upon NanoForge, the Company has\ndeveloped three technology solutions – AiTEM, AiLNP, and AiRNA – which can\nnot only significantly shorten drug development timelines but also enhance\ndrug safety and efficacy.\n\n * Differentiated Innovative Pipeline Covering Major Disease Areas Including\nImmunology, Oncology and Metabolic Diseases, Supported by a World-First\nIn Vivo Targeted Delivery System\nBased on the NanoForge platform, METiS TechBio has taken the lead in the\nindustry in achieving precision targeted delivery to eight key organs and\ntissues: the liver, lungs, heart, muscles, tumor tissues, immune system,\ncentral nervous system, and gastrointestinal tract. Its pipeline products\ncover oncology, immunology, central nervous system disorders, metabolic\ndiseases, and other areas.\n\nThe Company has more than 10 pipeline products, including several candidates\nat the discovery stage, four preclinical candidates, three clinical-stage\nproducts, one pre-NDA product, and two animal health products. As of the\nLatest Practicable Date, the Company had filed a total of 224 patent\napplications and had been granted 52 patents.\n\nMETiS TechBio has developed MTS-004, China's first AI-enabled formulation drug\nto complete a Phase III clinical trial. MTS-004 is the first and only PBA\n(pseudobulbar affect) drug in China to have completed clinical trials, and is\nexpected to fill the gap in PBA drug treatment in China. The MTS-004 program\ntook 38 months from project initiation to completion of the Phase III clinical\ntrial. Through AiTEM's predictive analytics and advanced modeling\ntechnologies, the Company successfully reduced preclinical formulation\ndevelopment time from one to two years to less than three months.\n\nThe \"rocket + satellite\" next-generation in vivo immunotherapy paradigm is a\ncore capability through which METiS TechBio advances the development of its\ndifferentiated innovation pipeline. MTS-105 is a benchmark pipeline product\ndesigned to efficiently activate anti-tumor immunity within specific organs in\nvivo, with the potential to become the world's first in vivo mRNA-encoded TCE\ntherapy for solid tumors, for the treatment of liver cancer and other advanced\nsolid tumors with liver metastases. Leveraging its AiLNP and AiRNA platforms,\nMETiS TechBio enables highly efficient expression of TCE in hepatocytes and\nliver cancer cells through specific liver-targeted LNP delivery, activating\npotent intratumoral immunity and thereby achieving powerful tumor cell\nkilling. MTS-105 is currently in the IIT stage and has received Orphan Drug\nDesignation from the U.S. FDA.\n\n * Dual Engines of Platform Collaborations and Product Partnerships, Reinforcing\nBarriers Through a Closed Loop of Technology Iteration, Commercial\nApplication, and Real-World Data Feedback\nIn terms of commercialization strategy, METiS TechBio adopts a \"platform\ncollaboration + product partnership\" dual-engine business model, forming a\nsynergistic and recycling ecosystem of \"technology iteration – commercial\napplication – real-world data feedback.\" To date, METiS TechBio has more\nthan 30 pharmaceutical and biotechnology partners worldwide, with customers\nprimarily including global top-tier pharmaceutical companies, innovative\nbiotechnology companies, and medical research institutions.\n\nMETiS TechBio recorded revenue of RMB 105 million in 2025, primarily from the\nupfront payment for the MTS-004 product partnership. The total milestones for\nMTS-004 in the PBA indication amount to RMB 1.845 billion, with additional\npotential milestone payments of up to RMB 100 million for potential indication\nexpansion. Meanwhile, a single-target contract in existing platform\ncollaborations is valued at up to USD 109 million. The dual-engine business\nmodel has been preliminarily validated by the market.\n\n * Core Senior Executives at the Founding-Team Level Joining Forces Across\nDisciplines, with Sustained Heavy Investment in R&D and Talent Development\nMETiS TechBio's R&D team is led by its three co-founders. Building upon\nthe Company's R&D centers in Beijing and Hangzhou, the team brings\ntogether multidisciplinary expertise spanning nanomaterials, chemistry,\nbiology, physics, computational science, medicine, and other fields, providing\nstrong support for innovation in AI nanodelivery and cross-disciplinary\nbreakthrough research. The R&D team comprises more than 100 scientists and\ntechnical personnel, including approximately 40 Ph.D. holders. The majority of\nthe Company's operating expenses are R&D-related, primarily including\nemployee benefits for scientists and engineers, share-based compensation\nexpenses, procurement of laboratory materials and equipment, and professional\nservice fees (including fees paid to CROs). From 2023 to 2025, the Company\nmaintained sustained high R&D expenditure of approximately RMB 270\nmillion.\n\nMETiS TechBio will always prioritize R&D as a key direction for strategic\ninvestment. Approximately 50.0% of the net proceeds from the IPO will be used\nto support core technology research, development, and advancement of its AI\ninfrastructure and AI-driven nanomaterials platform; approximately 20.0% will\nbe used for ongoing and planned clinical trials in its AI-developed product\npipeline, advancing candidate drugs across multiple therapeutic areas and\nmodalities; and approximately 10.0% will be used to develop animal health and\nanti-aging solutions and to expand AI-enabled solutions into these high-growth\nareas.\n\n(https://mma.prnewswire.com/media/2784498/TechBio_Logo.html)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/metis-techbio-the-worlds-first-publicly-listed-ai-powered-drug-delivery-company-debuts-on-the-hong-kong-stock-exchange-the-spacex-of-pharmaceuticals-ushers-in-a-new-era-of-biopharmaceuticals-302771717.html\n(https://www.prnewswire.com/news-releases/metis-techbio-the-worlds-first-publicly-listed-ai-powered-drug-delivery-company-debuts-on-the-hong-kong-stock-exchange-the-spacex-of-pharmaceuticals-ushers-in-a-new-era-of-biopharmaceuticals-302771717.html)\n\nSOURCE METiS TechBio\n\n\n\nYuqi Dong, yuqi.dong@metistechbio.com\n\nPhoto: \nhttps://mma.prnewswire.com/media/2979048/image1.jpg\nhttps://mma.prnewswire.com/media/2979049/image2.jpg\nhttps://mma.prnewswire.com/media/2784498/TechBio_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn2RgVmla","title":"METiS TechBio, the World's First Publicly Listed AI-Powered Drug Delivery Company, Debuts on the Hong Kong Stock Exchange, \"The SpaceX of Pharmaceuticals\" Ushers in a New Era of Biopharmaceuticals","author":"PR Newswire","ticker":"7666","created":"2026-05-14T02:10:01.569Z","tickers":["7666"],"exchange":"HKEX","article_body":"METiS TechBio, the World's First Publicly Listed AI-Powered Drug Delivery Company, Debuts on the Hong Kong Stock Exchange, \"The SpaceX of Pharmaceuticals\" Ushers in a New Era of Biopharmaceuticals\n\nPR Newswire\n\nHONG KONG, May 13, 2026\n\nHONG KONG, May 13, 2026 /PRNewswire/ -- METiS TechBio (7666.HK), a tech-bio\ncompany focused on AI-powered nanodelivery innovation, today successfully\nlisted on the Hong Kong Stock Exchange (HKEX), becoming the world's first\npublicly listed AI-powered drug delivery company and the first AI-powered\nlarge-molecule biopharmaceutical company listed on the Hong Kong market. With\nthe goal of becoming the \"SpaceX of pharmaceuticals,\" METiS TechBio has,\nwithin six years of its founding, become the fastest unicorn in China's AI\npharmaceutical sector to reach the IPO milestone.\n\nMETiS TechBio's IPO was jointly sponsored by Jefferies, Deutsche Bank\nSecurities Asia and CITIC Securities (Hong Kong). A total of 201,229,000 H\nshares were offered globally, raising over HKD 2.1 billion in proceeds and\nmarking the largest healthcare IPO fundraising in Hong Kong so far in 2026.\nThe Hong Kong public offering was oversubscribed by more than 6,900 times,\nlocking up over HKD 730 billion in subscription funds, representing the\nhighest subscription amount for the Hong Kong public offering among healthcare\nIPOs in Hong Kong so far in 2026. For the international placing, the Company\nreceived orders from more than 280 institutional investors and recorded 82\ntimes oversubscription for the allocable tranche, also marking the highest\ninternational placing oversubscription multiple among healthcare IPOs in Hong\nKong so far in 2026.\n\nMETiS TechBio's Hong Kong IPO once again set a record for AI pharmaceutical\nIPOs in Hong Kong with a top-tier lineup of 18 cornerstone investors\nsubscribing for a total of USD 148 million, securing comprehensive support\nfrom \"global asset managers + specialized healthcare funds + AI technology\nfunds + state-level funds + Chinese public fund managers.\" Among them,\nBlackRock, the world's largest asset manager, led the subscription with USD 50\nmillion. Global asset management giants and ultra-long-term funds including\nUBS Asset Management Singapore, Mirae Asset of South Korea, and ORIX\nCorporation of Japan collectively made allocations. Guofengtou Innovation\nInvestment Fund, a state-level fund, made its first investment in the AI\npharmaceutical sector. Internationally renowned specialist healthcare funds,\nincluding Deerfield, RTW and Lake Bleu Capital, participated in the\ninvestment, while leading technology investment institutions, including Walden\nInternational, Hillhouse Capital and IDG Capital, also expanded their presence\ninto the sector. Top Chinese public fund managers including GF Fund, ICBC UBS\nAsset Management, China Asset Management, and Fullgoal Fund also made a rare\njoint appearance as subscribers with lock-up commitments. This fully\ndemonstrates that AI nanodelivery technology has risen to the level of a\nnational strategic priority and key area of support, and has become a critical\ntechnology driving future growth and breakthroughs in global\nbiopharmaceuticals.\n\n(https://mma.prnewswire.com/media/2979048/image1.html)\n\nDr. Chris Lai, Co-Founder, Chairman and Chief Executive Officer of METiS\nTechBio, stated:\n\n\"The future of biomedicine will no longer be simply about 'taking medicine\nwhen one falls ill.' METiS TechBio's ambition is to harness AI to build\nnano-rockets that can navigate with precision through the inner space of the\nhuman body's 30 trillion cells, write the code of nucleic acids and proteins\ninto cells, and reprogram diseased and aging cells into healthy cells. This\nwas our founding aspiration, and it is the mission to which we will dedicate\nour lives. The IPO marks a new starting point for us to accelerate forward,\nand we will strive to live up to the support and trust we have received from\nall sectors.\"\n\n(https://mma.prnewswire.com/media/2979049/image2.html)\n\n \n\n * Proprietary World-First AI Nanodelivery Platform, Creating the First-Ever\nData, Algorithms, and Models for AI for Nano\nMETiS TechBio's core competitiveness stems from NanoForge, its proprietary\nworld-first AI nanodelivery platform. The Company has built the world's\nlargest ionizable lipid library at the scale of tens of millions,\nindependently developed the world's only algorithm for de novo lipid\ngeneration and lipid language model, established the world's first end-to-end\nlipid and lipid nanoparticle (LNP) screening platform, and created the world's\nfirst AI-powered multiscale simulation platform for small-molecule formulation\ndevelopment.\n\nNanoForge encompasses AI foundation models, METiS AI agents, quantum chemistry\nand molecular dynamics simulations, and an AI-driven high-throughput screening\nplatform, serving as the foundation of the Company's proprietary AI-driven\nnanotechnology innovation system. Building upon NanoForge, the Company has\ndeveloped three technology solutions – AiTEM, AiLNP, and AiRNA – which can\nnot only significantly shorten drug development timelines but also enhance\ndrug safety and efficacy.\n\n * Differentiated Innovative Pipeline Covering Major Disease Areas Including\nImmunology, Oncology and Metabolic Diseases, Supported by a World-First\nIn Vivo Targeted Delivery System\nBased on the NanoForge platform, METiS TechBio has taken the lead in the\nindustry in achieving precision targeted delivery to eight key organs and\ntissues: the liver, lungs, heart, muscles, tumor tissues, immune system,\ncentral nervous system, and gastrointestinal tract. Its pipeline products\ncover oncology, immunology, central nervous system disorders, metabolic\ndiseases, and other areas.\n\nThe Company has more than 10 pipeline products, including several candidates\nat the discovery stage, four preclinical candidates, three clinical-stage\nproducts, one pre-NDA product, and two animal health products. As of the\nLatest Practicable Date, the Company had filed a total of 224 patent\napplications and had been granted 52 patents.\n\nMETiS TechBio has developed MTS-004, China's first AI-enabled formulation drug\nto complete a Phase III clinical trial. MTS-004 is the first and only PBA\n(pseudobulbar affect) drug in China to have completed clinical trials, and is\nexpected to fill the gap in PBA drug treatment in China. The MTS-004 program\ntook 38 months from project initiation to completion of the Phase III clinical\ntrial. Through AiTEM's predictive analytics and advanced modeling\ntechnologies, the Company successfully reduced preclinical formulation\ndevelopment time from one to two years to less than three months.\n\nThe \"rocket + satellite\" next-generation in vivo immunotherapy paradigm is a\ncore capability through which METiS TechBio advances the development of its\ndifferentiated innovation pipeline. MTS-105 is a benchmark pipeline product\ndesigned to efficiently activate anti-tumor immunity within specific organs in\nvivo, with the potential to become the world's first in vivo mRNA-encoded TCE\ntherapy for solid tumors, for the treatment of liver cancer and other advanced\nsolid tumors with liver metastases. Leveraging its AiLNP and AiRNA platforms,\nMETiS TechBio enables highly efficient expression of TCE in hepatocytes and\nliver cancer cells through specific liver-targeted LNP delivery, activating\npotent intratumoral immunity and thereby achieving powerful tumor cell\nkilling. MTS-105 is currently in the IIT stage and has received Orphan Drug\nDesignation from the U.S. FDA.\n\n * Dual Engines of Platform Collaborations and Product Partnerships, Reinforcing\nBarriers Through a Closed Loop of Technology Iteration, Commercial\nApplication, and Real-World Data Feedback\nIn terms of commercialization strategy, METiS TechBio adopts a \"platform\ncollaboration + product partnership\" dual-engine business model, forming a\nsynergistic and recycling ecosystem of \"technology iteration – commercial\napplication – real-world data feedback.\" To date, METiS TechBio has more\nthan 30 pharmaceutical and biotechnology partners worldwide, with customers\nprimarily including global top-tier pharmaceutical companies, innovative\nbiotechnology companies, and medical research institutions.\n\nMETiS TechBio recorded revenue of RMB 105 million in 2025, primarily from the\nupfront payment for the MTS-004 product partnership. The total milestones for\nMTS-004 in the PBA indication amount to RMB 1.845 billion, with additional\npotential milestone payments of up to RMB 100 million for potential indication\nexpansion. Meanwhile, a single-target contract in existing platform\ncollaborations is valued at up to USD 109 million. The dual-engine business\nmodel has been preliminarily validated by the market.\n\n * Core Senior Executives at the Founding-Team Level Joining Forces Across\nDisciplines, with Sustained Heavy Investment in R&D and Talent Development\nMETiS TechBio's R&D team is led by its three co-founders. Building upon\nthe Company's R&D centers in Beijing and Hangzhou, the team brings\ntogether multidisciplinary expertise spanning nanomaterials, chemistry,\nbiology, physics, computational science, medicine, and other fields, providing\nstrong support for innovation in AI nanodelivery and cross-disciplinary\nbreakthrough research. The R&D team comprises more than 100 scientists and\ntechnical personnel, including approximately 40 Ph.D. holders. The majority of\nthe Company's operating expenses are R&D-related, primarily including\nemployee benefits for scientists and engineers, share-based compensation\nexpenses, procurement of laboratory materials and equipment, and professional\nservice fees (including fees paid to CROs). From 2023 to 2025, the Company\nmaintained sustained high R&D expenditure of approximately RMB 270\nmillion.\n\nMETiS TechBio will always prioritize R&D as a key direction for strategic\ninvestment. Approximately 50.0% of the net proceeds from the IPO will be used\nto support core technology research, development, and advancement of its AI\ninfrastructure and AI-driven nanomaterials platform; approximately 20.0% will\nbe used for ongoing and planned clinical trials in its AI-developed product\npipeline, advancing candidate drugs across multiple therapeutic areas and\nmodalities; and approximately 10.0% will be used to develop animal health and\nanti-aging solutions and to expand AI-enabled solutions into these high-growth\nareas.\n\n(https://mma.prnewswire.com/media/2784498/TechBio_Logo.html)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/metis-techbio-the-worlds-first-publicly-listed-ai-powered-drug-delivery-company-debuts-on-the-hong-kong-stock-exchange-the-spacex-of-pharmaceuticals-ushers-in-a-new-era-of-biopharmaceuticals-302771717.html\n(https://www.prnewswire.com/news-releases/metis-techbio-the-worlds-first-publicly-listed-ai-powered-drug-delivery-company-debuts-on-the-hong-kong-stock-exchange-the-spacex-of-pharmaceuticals-ushers-in-a-new-era-of-biopharmaceuticals-302771717.html)\n\nSOURCE METiS TechBio\n\n\n\nYuqi Dong, yuqi.dong@metistechbio.com\n\nPhoto: \nhttps://mma.prnewswire.com/media/2979048/image1.jpg\nhttps://mma.prnewswire.com/media/2979049/image2.jpg\nhttps://mma.prnewswire.com/media/2784498/TechBio_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-05-14T02:10:01.638311361Z","server_sent_at_ms":1778724601638},"received_at":"2026-05-14T02:10:01.693Z","source_url":"https://www.prnewswire.com/news-releases/metis-techbio-the-worlds-first-publicly-listed-ai-powered-drug-delivery-company-debuts-on-the-hong-kong-stock-exchange-the-spacex-of-pharmaceuticals-ushers-in-a-new-era-of-biopharmaceuticals-302771717.html"},"analysis":{"id":"24288","press_release_id":"34323","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"m_and_a","narrative":"METiS TechBio, the world's first publicly listed AI-powered drug delivery company, successfully listed on the Hong Kong Stock Exchange, raising over HKD 2.1 billion in gross proceeds.\n\nThe company's IPO was oversubscribed by more than 6,900 times in the Hong Kong public offering and 82 times in the international placing, setting multiple records for healthcare IPOs in Hong Kong.\n\nMETiS TechBio has developed MTS-004, China's first AI-enabled formulation drug to complete a Phase III clinical trial, with total milestones amounting to RMB 1.845 billion and potential additional payments of up to RMB 100 million.\n\nThe company's R&D team, led by its three co-founders, comprises more than 100 scientists and technical personnel, with a focus on sustained high R&D expenditure and talent development.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"METiS TechBio's record-breaking IPO and innovative AI nanodelivery platform position it as a leader in the biopharmaceutical sector."},"keyFigures":{"sharesOffered":201229000,"customDimensions":{"revenue_2025":105000000,"granted_patents":52,"pipeline_products":10,"patent_applications":224,"total_milestones_mts_004":1845000000,"single_target_contract_value":109000000,"r_and_d_expenditure_2023_2025":270000000,"potential_milestone_payments_mts_004":10000000}},"quotedText":"The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells.","namedEntities":{"people":[{"name":"Dr. Chris Lai","role":"Co-Founder, Chairman and Chief Executive Officer"}],"products":["ZENVIA","MTS-004","MTS-105","AiTEM","AiLNP","AiRNA"],"companies":[{"name":"METiS TechBio","ticker":"7666"},{"name":"Jefferies","relationship":"underwriter"},{"name":"Deutsche Bank Securities Asia","relationship":"underwriter"},{"name":"CITIC Securities (Hong Kong)","relationship":"underwriter"},{"name":"BlackRock","relationship":"cornerstone investor"},{"name":"UBS Asset Management Singapore","relationship":"cornerstone investor"},{"name":"Mirae Asset of South Korea","relationship":"cornerstone investor"},{"name":"ORIX Corporation of Japan","relationship: ":"cornerstone investor"},{"name":"Guofengtou Innovation Investment Fund","relationship":"cornerstone investor"},{"name":"Deerfield","relationship":"cornerstone investor"},{"name":"RTW","relationship":"cornerstone investor"},{"name":"Lake Bleu Capital","relationship":"cornerstone investor"},{"name":"Walden International","relationship":"cornerstone investor"},{"name":"Hillhouse Capital","relationship":"cornerstone investor"},{"name":"IDG Capital","relationship":"cornerstone investor"},{"name":"GF Fund","relationship":"cornerstone investor"},{"name":"ICBC UBS Asset Management","relationship":"cornerstone investor"},{"name":"China Asset Management","relationship":"cornerstone investor"},{"name":"Fullgoal Fund","relationship":"cornerstone investor"}],"dollarAmounts":[{"amount":"HKD 2.1 billion","context":"gross proceeds from IPO"},{"amount":"HKD 730 billion","context":"subscription funds for Hong Kong public offering"},{"amount":"USD 148 million","context":"total cornerstone investor subscriptions"},{"amount":"USD 50 million","context":"BlackRock's subscription"},{"amount":"USD 109 million","context":"value of a single-target contract in platform collaborations"},{"amount":"RMB 105 million","context":"2025 revenue"},{"amount":"RMB 1.845 billion","context":"total milestones for MTS-004 in PBA indication"},{"amount":"RMB 100 million","context":"potential milestone payments for MTS-004 indication expansion"},{"amount":"RMB 270 million","context":"sustained high R&D expenditure from 2023 to 2025"}]},"materialImpact":{"score":5,"reasoning":"METiS TechBio successfully listed on the Hong Kong Stock Exchange, raising significant capital and setting multiple records. The company's innovative AI nanodelivery platform and strong pipeline of products, including a Phase III drug, position it as a leader in the biopharmaceutical sector."},"tickerRelevance":{"others":[],"primary":"7666"},"globalImportance":75,"audienceRelevance":80,"eventTypeSecondary":["product_launch","operations_update"],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"IPO and record-breaking fundraising","sectorWeight":"Health Care","householdBrandBoost":"high","retailFavoriteBoost":"moderate"}},"event_type":"m_and_a","event_type_secondary":["product_launch","operations_update"],"sentiment":"bullish","material_impact_score":5,"narrative":"METiS TechBio, the world's first publicly listed AI-powered drug delivery company, successfully listed on the Hong Kong Stock Exchange, raising over HKD 2.1 billion in gross proceeds.\n\nThe company's IPO was oversubscribed by more than 6,900 times in the Hong Kong public offering and 82 times in the international placing, setting multiple records for healthcare IPOs in Hong Kong.\n\nMETiS TechBio has developed MTS-004, China's first AI-enabled formulation drug to complete a Phase III clinical trial, with total milestones amounting to RMB 1.845 billion and potential additional payments of up to RMB 100 million.\n\nThe company's R&D team, led by its three co-founders, comprises more than 100 scientists and technical personnel, with a focus on sustained high R&D expenditure and talent development.","key_figures":{"sharesOffered":201229000,"customDimensions":{"revenue_2025":105000000,"granted_patents":52,"pipeline_products":10,"patent_applications":224,"total_milestones_mts_004":1845000000,"single_target_contract_value":109000000,"r_and_d_expenditure_2023_2025":270000000,"potential_milestone_payments_mts_004":10000000}},"named_entities":{"people":[{"name":"Dr. Chris Lai","role":"Co-Founder, Chairman and Chief Executive Officer"}],"products":["ZENVIA","MTS-004","MTS-105","AiTEM","AiLNP","AiRNA"],"companies":[{"name":"METiS TechBio","ticker":"7666"},{"name":"Jefferies","relationship":"underwriter"},{"name":"Deutsche Bank Securities Asia","relationship":"underwriter"},{"name":"CITIC Securities (Hong Kong)","relationship":"underwriter"},{"name":"BlackRock","relationship":"cornerstone investor"},{"name":"UBS Asset Management Singapore","relationship":"cornerstone investor"},{"name":"Mirae Asset of South Korea","relationship":"cornerstone investor"},{"name":"ORIX Corporation of Japan","relationship: ":"cornerstone investor"},{"name":"Guofengtou Innovation Investment Fund","relationship":"cornerstone investor"},{"name":"Deerfield","relationship":"cornerstone investor"},{"name":"RTW","relationship":"cornerstone investor"},{"name":"Lake Bleu Capital","relationship":"cornerstone investor"},{"name":"Walden International","relationship":"cornerstone investor"},{"name":"Hillhouse Capital","relationship":"cornerstone investor"},{"name":"IDG Capital","relationship":"cornerstone investor"},{"name":"GF Fund","relationship":"cornerstone investor"},{"name":"ICBC UBS Asset Management","relationship":"cornerstone investor"},{"name":"China Asset Management","relationship":"cornerstone investor"},{"name":"Fullgoal Fund","relationship":"cornerstone investor"}],"dollarAmounts":[{"amount":"HKD 2.1 billion","context":"gross proceeds from IPO"},{"amount":"HKD 730 billion","context":"subscription funds for Hong Kong public offering"},{"amount":"USD 148 million","context":"total cornerstone investor subscriptions"},{"amount":"USD 50 million","context":"BlackRock's subscription"},{"amount":"USD 109 million","context":"value of a single-target contract in platform collaborations"},{"amount":"RMB 105 million","context":"2025 revenue"},{"amount":"RMB 1.845 billion","context":"total milestones for MTS-004 in PBA indication"},{"amount":"RMB 100 million","context":"potential milestone payments for MTS-004 indication expansion"},{"amount":"RMB 270 million","context":"sustained high R&D expenditure from 2023 to 2025"}]},"model_name":"Qwen/Qwen2.5-72B-Instruct-AWQ","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-14T02:11:48.220Z","global_importance":75,"audience_relevance":80,"importance_components":{"tickerTier":"mid-cap","eventGravity":"IPO and record-breaking fundraising","sectorWeight":"Health Care","householdBrandBoost":"high","retailFavoriteBoost":"moderate"}},"durationMs":106504,"modelName":"george-droid-qwen-72b"}}